Table 2.
Effect of MYQ on cardiac function
| Sham (n = 10) | I/R (1 week) | I/R (1 month) | |||||
|---|---|---|---|---|---|---|---|
| I/R (n = 10) | Low dose (n = 10) | High dose (n = 9) | I/R (n = 10) | Low dose (n = 10) | High dose (n = 9) | ||
| HR (bpm) | 403.8 ± 20.8 | 354.8 ± 50.8 | 374.6 ± 26.5 | 443.6 ± 18.9 | 310.8 ± 22.4 | 355.7 ± 34.0 | 394.0 ± 41.8 |
| RRI (ms) | 147.9 ± 6.8 | 185.8 ± 28.3 | 163.3 ± 11.7 | 136.3 ± 6.3 | 203.7 ± 22.4 | 179.7 ± 17.0 | 166.8 ± 29.1 |
| SA P(mmHg) | 91.7 ± 3.4 | 80.8 ± 2.2* | 70.2 ± 13.3 | 68.1 ± 4.7 | 57.5 ± 2.1* | 72.4 ± 9.2† | 82.3 ± 3.3 |
| DAP (mmHg) | 82.2 ± 2.8 | 50.0 ± 2.4* | 45.9 ± 11.2 | 54.3 ± 5.5 | 44.8 ± 1.0* | 50.5 ± 8.0 | 61.7 ± 3.8 |
| MAP (mmHg) | 86.8 ± 2.3 | 61.9 ± 1.8* | 55.9 ± 11.7 | 60.7 ± 4.9 | 50.8 ± 0.9* | 59.0 ± 8.2 | 70.7 ± 3.6 |
| PP (mmHg) | 9.5 ± 3.7 | 30.7 ± 2.4* | 24.3 ± 4.2 | 13.7 ± 3.2 | 12.7 ± 2.5 | 21.9 ± 2.2 | 20.5 ± 1.1 |
| Pmax (mmHg) | 100.5 ± 7.5 | 87.6 ± 1.8* | 82.7 ± 10.5 | 98.3 ± 6.0† | 80.5 ± 2.1* | 90.8 ± 6.8† | 105.5 ± 3.1† |
| Pmin (mmHg) | 2.8 ± 0.9 | 5.8 ± 0.4* | 5.5 ± 1.9 | 5.1 ± 3.8 | 7.8 ± 1.9* | 11.0 ± 3.4 | 2.4 ± 1.9† |
| Pmean (mmHg) | 54.9 ± 2.8 | 42.8 ± 1.4* | 40.5 ± 7.2 | 49.8 ± 1.5† | 37.9 ± 0.9* | 41.9 ± 5.0† | 51.4 ± 1.7† |
| Lvedp (mmHg) | 15.4 ± 2.3 | 41.9 ± 14.3* | 30.6 ± 13.2 | 41.0 ± 6.7 | 19.5 ± 3.7* | 18.6 ± 6.4 | 37.6 ± 3.4 |
| P@dp/dtmax (mmHg) | 67.8 ± 8.6 | 67.0 ± 3.2 | 64.1 ± 11.6 | 83.9 ± 5.1 | 57.3 ± 1.2 | 64.8 ± 7.3 | 87.0 ± 3.5 |
| P@-dp/dtmax (mmHg) | 69.5 ± 3.8 | 46.1 ± 1.1 | 46.7 ± 7.5 | 49.0 ± 2.6 | 47.0 ± 2.7 | 50.2 ± 5.8 | 50.3 ± 1.8 |
| RPP | 33,425 ± 7359 | 30,482 ± 4066 | 31,914 ± 5969 | 43,830 ± 3697 | 25,151 ± 1953 | 33,544 ± 5012 | 42,123 ± 5324 |
| dp/dtmax (mmHg/s) | 4943 ± 142 | 3637 ± 168* | 3247 ± 299 | 3744 ± 323† | 3452 ± 240* | 4078 ± 643† | 4125 ± 146† |
| -dp/dtmax (mmHg/s) | −4479 ± 155 | −3893 ± 149* | −3223 ± 567 | −4167 ± 678† | −2753 ± 315* | −3161 ± 487† | 4528 ± 358† |
| At (CFL)(CFU) | 102.8 ± 52.1 | 65.5 ± 108* | 40.8 ± 9.9 | 52.7 ± 11.3 | 37.9 ± 2.5* | 48.3 ± 9.7† | 72.9 ± 3.8† |
| A1 (CFL)(CFU) | 9.7 ± 3.5 | 24.7 ± 9.5* | 7.5 ± 0.8 | 10.7 ± 1.5† | 9.0 ± 1.4 | 13.3 ± 3.1† | 13.9 ± 1.2† |
| A2 (CFL)(CFU) | 12.5 ± 2.0 | 10.5 ± 1.2* | 8.6 ± 1.1 | 9.8 ± 1.5 | 10.4 ± 1.3* | 4.41 ± 2.9† | 12.4 ± 0.7† |
| A3 (CFL)(CFU) | 10.4 ± 3.1 | 12.8 ± 0.7 | 10.5 ± 2.9 | 15.8 ± 3.9 | 7.6 ± 1.1* | 10.0 ± 2.0† | 18.3 ± 2.0† |
| A4 (CFL)(CFU) | 70.2 ± 49.8 | 17.5 ± 2.1* | 14.2 ± 5.6 | 16.4 ± 5.7 | 10.9 ± 1.8* | 10.6 ± 2.1 | 28.4 ± 5.3† |
| As (CFL)(CFU) | 22.2 ± 5.4 | 35.2 ± 9.1* | 16.1 ± 1.9† | 20.5 ± 2.8† | 19.4 ± 2.6* | 27.7 ± 5.9† | 26.2 ± 1.9† |
| Ad (CFL)(CFU) | 80.6 ± 50.2 | 30.3 ± 2.2* | 24.7 ± 8.4 | 32.2 ± 9.5 | 18.5 ± 1.0* | 20.6 ± 4.1 | 45.7 ± 3.6† |
| Smax (CRHL) | 160.4 ± 49.6 | 138.0 ± 89.4 | 214.9 ± 27.3 | 271.3 ± 43.9 | 239.4 ± 17.1* | 278.2 ± 68.4 | 263.7 ± 18.2† |
| Smin (CRHL)(mmHg2/s2) | −202.2 ± 87.0 | −274.2 ± 25.9 | −248.3 ± 40.0 | −389.5 ± 56.9 | −240.7 ± 25.6 | −350.5 ± 88.0 | −392.3 ± 31.1† |
| Dmax (CRHL)(mmHg2/s) | 155.9 ± 66.0 | 302.3 ± 25.5* | 210.1 ± 1.2 | 303.5 ± 98.8 | 168.6 ± 16.7 | 228.6 ± 57.6 | 348.7 ± 42.1† |
| Dmin (CRHL)(mmHg2/s2) | −191.9 ± 16.8 | −276.1 ± 17.8* | −190.0 ± 43.6 | −315.7 ± 55.9 | −164.9 ± 18.7* | −211.3 ± 49.1† | −313.8 ± 34.1† |
Table 2: cardiac function parameters. HR (Heart rate), RRI (the R-R interval), SAP (Systolic arterial pressure), DAP (Diastolic arterial pressure), MAP (Mean arterial pressure), PP (Pulse pressure), Pmax (the maximum of left ventricular pressure development), Pmin (the minimum of left ventricular pressure development), Pmean (the mean of ventricular pressure development), LVEDP (left ventricular end-diastolic pressure), P@dp/dtmax (the left ventricular pressure corresponding to the rates of maximum positive left ventricular pressure development), P@-dp/dtmax (the left ventricular pressure corresponding to the rates of maximum negative left ventricular pressure development), RPP (rate pressure product), +dp/dtmax (rates of maximum positive left ventricular pressure development), −dp/dtmax (rates of maximum negative left ventricular pressure development), CFL (cardiac force loop), At(CFL) (total area of CFL), A1(CFL) (area of the first CFL), A2(CFL) (area of the second CFL), A3(CFL) (area of the third CFL), A4(CFL) (area of the fourth CFL), As(CFL) (systolic area of CFL), Ad(CFL) (diastolic area of CFL), CRHL (contraction relaxation harmoniousness loop), Smax (CRHL) (the maximum of positive left ventricular systolic pressure of d2p/dt2), Smin (CRHL) (the maximum of negative left ventricular systolic pressure of d2p/dt2), Dmax (CRHL) (the maximum of positive left ventricular diastolic pressure of d2p/dt2),Dmin (CRHL) (the maximum of negative left ventricular diastolic pressure of d2p/dt2) were measured by a cardiac function analysis system. Values were expressed as mean ± S.E.M. Sham: Sham group; I/R: ischemic/reperfusion group. Low dose: I/R + (1 ml) MYQ treatment group. High dose: I/R + (4 ml) MYQ treatment group. *P < 0.05 compared with sham group. †P < 0.05 compared with I/R group